The case for & against
Bull & Bear analysis
Bearish
Doximity, Inc. (NYSE: DOCS) is a leading digital platform in the healthcare technology sector, primarily serving healthcare providers through telehealth solutions and clinical resource management. With a substantial network encompassing over 85% of U.S. physicians, Doximity aims to enhance clinical workflows using innovative AI tools. Positioned uniquely at the intersection of healthcare and technology, the company is focused on increasingly integrating AI innovations to improve service efficiency and capture a growing market for digital healthcare solutions.
Bull says
- ↑Q4 revenue rose to $145M (+5% YoY); FY27 guide of $664–676M implies ~4% growth
- ↑Record Q4 free cash flow of $107M (+11% YoY); FY26 FCF $317M (49% of revenue)
- ↑109% net revenue retention underlines strong client loyalty and upsell potential
- ↑$91M in Q4 buybacks ($432M FY26) highlights management confidence
- ↑“AI investment year” with multi-billion TAM in AI search drives future growth
- ↑High earnings yield and strong profitability support valuation amid robust growth
Bear says
- ↓Healthcare policy uncertainty may curb pharma budgets and client commitments
- ↓Rising AI compute costs are squeezing adjusted EBITDA margins
- ↓Volatility in share price deters risk-averse investors amid 3×-normal swings
- ↓Top 20 clients account for 80%+ revenue; any cuts would hit revenue materially
- ↓Shift to shorter-term contracts reduces revenue visibility and forecasting accuracy
- ↓Balance-sheet concerns, low dividend yield and small-cap challenges warrant caution
Investment themes with DOCS
Health Care Providers↓ -0.61%
UNH · CVS · HCA
Earnings Call · Q4 2026 · Mgmt. Guidance
Updated 05-14-2026neutral
Transcript signals
Bull points
- I see it as a company that has just incredible platform potential along the ways of other companies that I've been privileged to be a part of, like LinkedIn, like Atlassian, an incredible brand, like DocuSign.
- our pharma ad business in particular can really evolve from here into that search ad market. And that's something that LinkedIn did an incredible job over multiple years was evolving its ad business.
- And Doximity is seeing that right now, you know, really driven by the AI engagement. So I think that's just a really exciting kind of, longer-term framing opportunity to think about how AI monetization really starts to play into the model.
Bear points
- The primary driver for the change in EBITDA margin versus last year is our increased investment in AI compute, driven by a steep ramp in AI usage, which is outgrowing overall workflow engagement.
- We are witnessing a continuation of the trend discussed on our last call with short-term demand in the HCP digital pharma ad market soft and visibility still limited.
- This market environment is the result of policy uncertainty remaining elevated and increased macro risk, taking together we expect overall market growth to be modest this year, likely at or below 5%.
Read full transcript analysis ›